Ozempic®

Ozempic® is the brand name for semaglutide, manufactured by Novo Nordisk. It's FDA-approved for improving blood sugar control in adults with type 2 diabetes and has become widely prescribed off-label for weight management due to its significant appetite-suppressing effects.

Ozempic® works by mimicking GLP-1, a naturally occurring hormone that regulates blood sugar and appetite. At altRx, Ozempic® is prescribed through licensed clinicians who evaluate your medical history and weight loss goals to create a personalized treatment plan with ongoing telehealth support.

Ozempic® is the FDA-approved brand-name medication manufactured by Novo Nordisk, while compounded semaglutide is prepared by specialized compounding pharmacies. Both contain the same active ingredient—semaglutide—but differ in formulation, device, and cost.

Ozempic® comes in pre-filled FlexTouch® pens with precise, pre-set doses, while compounded versions typically require manual dosing from vials. Ozempic® may be covered by insurance for diabetes (though rarely for weight loss), while compounded semaglutide is typically more affordable for self-pay patients. Your clinician will help determine the best option based on your needs and budget.

Ozempic® activates GLP-1 receptors throughout the body, triggering multiple beneficial effects. In the brain, it reduces appetite signals and increases satiety. In the stomach, it slows digestion, helping you feel fuller longer. In the pancreas, it enhances insulin secretion while suppressing glucagon, improving blood sugar control.

Clinical studies show Ozempic® users lost an average of 12-15% of their body weight when combined with lifestyle modifications. The SUSTAIN clinical trial program also demonstrated significant cardiovascular benefits, including reduced risk of heart attack and stroke in patients with type 2 diabetes and cardiovascular disease.

Most people notice a significant decrease in appetite within the first week of starting Ozempic®. Food cravings diminish, portions become more satisfying, and the urge to snack between meals naturally fades. You'll likely find yourself feeling full faster and staying satisfied longer.

Initial side effects may include mild to moderate nausea, occasional indigestion, or changes in bowel movements—these typically improve within 2-4 weeks. Dosing starts low (0.25mg) and increases gradually every 4 weeks, allowing your body to adjust. Many users report consistent, steady weight loss alongside improved blood sugar levels and increased energy.

Administration: Once-weekly subcutaneous injection using pre-filled FlexTouch® pen
Dosing: Starts at 0.25mg weekly for 4 weeks, then 0.5mg weekly; can increase to 1mg or 2mg based on response and tolerance
Storage: Refrigerate unused pens (36-46°F); after first use, can be kept at room temperature (59-86°F) or refrigerated for up to 56 days
Manufacturer: Novo Nordisk